Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:FOLD NASDAQ:INVA NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$26.83+1.1%$24.56$14.40▼$29.38$1.76B1.331.05 million shs704,642 shsFOLDAmicus Therapeutics$8.04-0.9%$7.88$5.51▼$12.65$2.50B0.565.81 million shs3.12 million shsINVAInnoviva$17.27+0.1%$19.22$16.52▼$22.00$1.09B0.4765,889 shs760,832 shsLGNDLigand Pharmaceuticals$181.65+0.5%$167.66$93.58▼$186.48$3.54B0.95166,914 shs156,792 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+1.05%+0.22%+9.69%+19.72%-9.72%FOLDAmicus Therapeutics-0.86%-3.13%+0.88%+34.90%-23.43%INVAInnoviva+0.12%-0.46%-10.89%-11.75%-14.55%LGNDLigand Pharmaceuticals+0.49%+2.21%+9.82%+30.59%+69.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$26.83+1.1%$24.56$14.40▼$29.38$1.76B1.331.05 million shs704,642 shsFOLDAmicus Therapeutics$8.04-0.9%$7.88$5.51▼$12.65$2.50B0.565.81 million shs3.12 million shsINVAInnoviva$17.27+0.1%$19.22$16.52▼$22.00$1.09B0.4765,889 shs760,832 shsLGNDLigand Pharmaceuticals$181.65+0.5%$167.66$93.58▼$186.48$3.54B0.95166,914 shs156,792 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+1.05%+0.22%+9.69%+19.72%-9.72%FOLDAmicus Therapeutics-0.86%-3.13%+0.88%+34.90%-23.43%INVAInnoviva+0.12%-0.46%-10.89%-11.75%-14.55%LGNDLigand Pharmaceuticals+0.49%+2.21%+9.82%+30.59%+69.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.50Moderate Buy$43.7863.17% UpsideFOLDAmicus Therapeutics 2.80Moderate Buy$15.8897.45% UpsideINVAInnoviva 2.71Moderate Buy$37.60117.72% UpsideLGNDLigand Pharmaceuticals 2.71Moderate Buy$176.50-2.84% DownsideCurrent Analyst Ratings BreakdownLatest INVA, LGND, FOLD, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025CLDXCelldex TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$25.0010/8/2025CLDXCelldex TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FOLDAmicus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025INVAInnovivaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/6/2025FOLDAmicus TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/27/2025CLDXCelldex TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FOLDAmicus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M253.81N/AN/A$11.26 per share2.38FOLDAmicus Therapeutics$571.16M4.34N/AN/A$0.65 per share12.37INVAInnoviva$358.71M3.03$3.43 per share5.04$11.03 per share1.57LGNDLigand Pharmaceuticals$187.58M18.98$1.61 per share112.50$43.95 per share4.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A18.70N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)INVAInnoviva$23.39M$0.3155.7111.14N/A10.44%18.67%9.92%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A48.96N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)Latest INVA, LGND, FOLD, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025LGNDLigand Pharmaceuticals$1.96N/AN/AN/A$58.71 millionN/A11/5/2025Q3 2025CLDXCelldex Therapeutics-$0.88N/AN/AN/A$1.12 millionN/A11/5/2025Q3 2025FOLDAmicus Therapeutics$0.12N/AN/AN/A$165.24 millionN/A11/5/2025Q3 2025INVAInnoviva$0.46N/AN/AN/A$91.31 millionN/A8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A19.6719.67FOLDAmicus Therapeutics1.923.212.29INVAInnoviva0.362.642.44LGNDLigand PharmaceuticalsN/A5.455.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/AINVAInnoviva99.12%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%FOLDAmicus Therapeutics2.20%INVAInnoviva2.25%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableINVA, LGND, FOLD, and CLDX HeadlinesRecent News About These CompaniesLigand Pharmaceuticals (NASDAQ:LGND) Hits New 12-Month High - Here's WhyOctober 17 at 10:59 AM | marketbeat.comTweedy Browne Co LLC Takes Position in Ligand Pharmaceuticals Incorporated $LGNDOctober 17 at 7:13 AM | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Position Decreased by Blair William & Co. ILOctober 17 at 3:23 AM | marketbeat.comLigand to Host Investor Day on December 9, 2025October 16 at 7:00 AM | globenewswire.comEquitable Trust Co. Acquires 1,710 Shares of Ligand Pharmaceuticals Incorporated $LGNDOctober 16 at 5:00 AM | marketbeat.comAberdeen Group plc Has $26.06 Million Holdings in Ligand Pharmaceuticals Incorporated $LGNDOctober 14, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 13, 2025 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 13, 2025 | marketbeat.comVillere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGNDOctober 11, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comLigand partner SQ Innovation receives approval from FDA for Lasix ONYUOctober 9, 2025 | msn.comLigand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure PatientsOctober 9, 2025 | quiverquant.comQLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure PatientsOctober 9, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year High - Here's What HappenedOctober 6, 2025 | marketbeat.comJohn Kozarich Sells 467 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockOctober 4, 2025 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 SharesOctober 3, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Purchased by Chicago Capital LLCSeptember 30, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month High - What's Next?September 29, 2025 | marketbeat.comCongress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGNDSeptember 26, 2025 | marketbeat.comJason Aryeh Sells 10,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockSeptember 25, 2025 | insidertrades.comArecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292September 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINVA, LGND, FOLD, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$26.83 +0.28 (+1.05%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$26.84 +0.01 (+0.02%) As of 10/17/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$8.04 -0.07 (-0.86%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$8.04 0.00 (-0.06%) As of 10/17/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Innoviva NASDAQ:INVA$17.27 +0.02 (+0.12%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$16.87 -0.40 (-2.32%) As of 10/17/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Ligand Pharmaceuticals NASDAQ:LGND$181.65 +0.88 (+0.49%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$181.76 +0.10 (+0.06%) As of 10/17/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
